CA2335773A1 - Une methode pour evaluer la situation biologique d'une pathologie dans un tissu epithelial - Google Patents
Une methode pour evaluer la situation biologique d'une pathologie dans un tissu epithelial Download PDFInfo
- Publication number
- CA2335773A1 CA2335773A1 CA 2335773 CA2335773A CA2335773A1 CA 2335773 A1 CA2335773 A1 CA 2335773A1 CA 2335773 CA2335773 CA 2335773 CA 2335773 A CA2335773 A CA 2335773A CA 2335773 A1 CA2335773 A1 CA 2335773A1
- Authority
- CA
- Canada
- Prior art keywords
- enterocytes
- cells
- cancer
- sample
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 130
- 210000000981 epithelium Anatomy 0.000 title claims abstract description 52
- 230000007170 pathology Effects 0.000 title claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 166
- 201000011510 cancer Diseases 0.000 claims abstract description 129
- 210000001519 tissue Anatomy 0.000 claims abstract description 59
- 238000011161 development Methods 0.000 claims abstract description 30
- 241001465754 Metazoa Species 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 230000001575 pathological effect Effects 0.000 claims abstract description 10
- 230000009826 neoplastic cell growth Effects 0.000 claims abstract description 8
- 208000006994 Precancerous Conditions Diseases 0.000 claims abstract description 5
- 238000004113 cell culture Methods 0.000 claims abstract description 3
- 210000001072 colon Anatomy 0.000 claims description 61
- 239000003153 chemical reaction reagent Substances 0.000 claims description 49
- 206010009944 Colon cancer Diseases 0.000 claims description 35
- 238000001574 biopsy Methods 0.000 claims description 34
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 33
- 210000003097 mucus Anatomy 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 27
- 238000010186 staining Methods 0.000 claims description 26
- 230000000968 intestinal effect Effects 0.000 claims description 19
- 150000003904 phospholipids Chemical class 0.000 claims description 18
- 239000000090 biomarker Substances 0.000 claims description 17
- 229960002523 mercuric chloride Drugs 0.000 claims description 13
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 claims description 13
- 239000011521 glass Substances 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000004040 coloring Methods 0.000 claims description 6
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 4
- 230000004807 localization Effects 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- 239000012192 staining solution Substances 0.000 claims description 3
- 238000012512 characterization method Methods 0.000 claims description 2
- 150000001805 chlorine compounds Chemical class 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 210000001842 enterocyte Anatomy 0.000 abstract description 70
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 15
- 230000036952 cancer formation Effects 0.000 abstract description 13
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 6
- 230000004044 response Effects 0.000 abstract description 5
- 238000005259 measurement Methods 0.000 abstract description 4
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 191
- 210000000130 stem cell Anatomy 0.000 description 81
- 150000002632 lipids Chemical class 0.000 description 30
- 230000018109 developmental process Effects 0.000 description 28
- 239000000523 sample Substances 0.000 description 27
- 239000000463 material Substances 0.000 description 26
- 230000000112 colonic effect Effects 0.000 description 25
- 239000008187 granular material Substances 0.000 description 21
- 230000003902 lesion Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 210000002175 goblet cell Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000012216 screening Methods 0.000 description 13
- 108090000288 Glycoproteins Proteins 0.000 description 12
- 102000003886 Glycoproteins Human genes 0.000 description 12
- 208000037062 Polyps Diseases 0.000 description 12
- 230000001594 aberrant effect Effects 0.000 description 12
- 230000001744 histochemical effect Effects 0.000 description 12
- 210000000822 natural killer cell Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 206010020718 hyperplasia Diseases 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 230000009466 transformation Effects 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 8
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 8
- 230000036210 malignancy Effects 0.000 description 8
- 239000003471 mutagenic agent Substances 0.000 description 8
- 231100000707 mutagenic chemical Toxicity 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 210000004739 secretory vesicle Anatomy 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 231100000357 carcinogen Toxicity 0.000 description 7
- 239000003183 carcinogenic agent Substances 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 230000007613 environmental effect Effects 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 210000004347 intestinal mucosa Anatomy 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108090001090 Lectins Proteins 0.000 description 5
- 102000004856 Lectins Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000000711 cancerogenic effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 239000000834 fixative Substances 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 5
- 229910052753 mercury Inorganic materials 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 210000002955 secretory cell Anatomy 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 4
- 108010046016 Peanut Agglutinin Proteins 0.000 description 4
- 230000002380 cytological effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000007784 diverticulitis Diseases 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 3
- 210000003892 absorptive cell Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002052 colonoscopy Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 230000001855 preneoplastic effect Effects 0.000 description 3
- 238000009117 preventive therapy Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 2
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 2
- 208000004804 Adenomatous Polyps Diseases 0.000 description 2
- ATSKDYKYMQVTGH-DNCUWRPASA-N Amaranthin Natural products O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2c(O)cc3/[N+](=C\C=C\4/C=C(C(=O)O)N[C@@H](C(=O)O)C/4)/[C@@H](C(=O)[O-])Cc3c2)O1 ATSKDYKYMQVTGH-DNCUWRPASA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010015133 Galactose oxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- ATSKDYKYMQVTGH-POBNKHOBSA-N amaranthin Chemical compound [N+]1([C@H](C([O-])=O)CC=2C=C(C(=CC=21)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@H](O1)C(O)=O)O)O)CO)=C\C=C1/C[C@@H](C(O)=O)NC(C(O)=O)=C1 ATSKDYKYMQVTGH-POBNKHOBSA-N 0.000 description 2
- 210000001815 ascending colon Anatomy 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003256 environmental substance Substances 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000012736 histometric measurement Methods 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003134 paneth cell Anatomy 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101000972289 Mus musculus Mucin-2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- -1 aldehyde compounds Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000012735 histological processing Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000029565 malignant colon neoplasm Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001915 nurse cell Anatomy 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 208000014965 pancolitis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000034394 regulation of mitosis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000812 repeated exposure Toxicity 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000002579 sigmoidoscopy Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2335773 CA2335773A1 (fr) | 2000-02-17 | 2001-02-13 | Une methode pour evaluer la situation biologique d'une pathologie dans un tissu epithelial |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2,299,210 | 2000-02-17 | ||
| CA002299210A CA2299210A1 (fr) | 2000-02-17 | 2000-02-17 | Une methode pour evaluer la situation biologique du developpement d'un cancer |
| CA 2335773 CA2335773A1 (fr) | 2000-02-17 | 2001-02-13 | Une methode pour evaluer la situation biologique d'une pathologie dans un tissu epithelial |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2335773A1 true CA2335773A1 (fr) | 2001-08-17 |
Family
ID=25681562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2335773 Abandoned CA2335773A1 (fr) | 2000-02-17 | 2001-02-13 | Une methode pour evaluer la situation biologique d'une pathologie dans un tissu epithelial |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2335773A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113620357A (zh) * | 2021-08-04 | 2021-11-09 | 中国科学院广州地球化学研究所 | 一种OsO2球型纳米颗粒材料的制备方法 |
-
2001
- 2001-02-13 CA CA 2335773 patent/CA2335773A1/fr not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113620357A (zh) * | 2021-08-04 | 2021-11-09 | 中国科学院广州地球化学研究所 | 一种OsO2球型纳米颗粒材料的制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020022240A1 (en) | Method of assessing the biological status of cancer development | |
| Jiang et al. | Alpha‐methylacyl‐CoA racemase: a multi‐institutional study of a new prostate cancer marker | |
| Cindolo et al. | Chromophobe renal cell carcinoma: comprehensive analysis of 104 cases from multicenter European database | |
| Tominaga et al. | Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma | |
| US5416025A (en) | Screening test for early detection of colorectal cancer | |
| Albe et al. | Independent prognostic value of ploidy in colorectal cancer. A prospective study using image cytometry | |
| Moonen et al. | Urinary NMP22® BladderChek® test in the diagnosis of superficial bladder cancer | |
| WO2022012282A1 (fr) | Marqueur de tcr de sang périphérique pour le cancer du foie, et son kit de détection et son utilisation | |
| JP2004536275A (ja) | ５，１０，１５，２０−テトラキス（カルボキシフェニル）ポルフィンを使用する、細胞および組織サンプルにおける前がん症状を検出するための組成物および方法 | |
| IT201800007264A1 (it) | Metodo per la diagnosi in vitro di carcinoma della prostata mediante biomarcatori urinari | |
| Habermann et al. | Ulcerative Colitis and Colorectal Carcinoma: DNA-Profile, Laminin-5? 2 Chain and Cyclin A Expression as Early Markers for Risk Assessment | |
| Manfrin et al. | Bcl-10, trypsin and synaptophysin helps recognize acinar cell and mixed acinar neuroendocrine cell carcinoma of the pancreas on both preoperative cytological samples and needle biopsy specimens | |
| Zaccaro et al. | Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT | |
| Çalapkulu et al. | Tumor volume can be used as a parameter indicating the severity of disease in parathyroid cancer | |
| CA2253093A1 (fr) | Test de depistage pour la detection precoce du cancer colorectal | |
| Abdulganieva et al. | Faecal Neutrophil Gelatinase-associated Lipocalin as a Non-invasive Biomarker in Inflammatory Bowel Disease | |
| US5942396A (en) | Method for identifying individuals at risk for colorectal neoplasia by quantifying normal colonic mucosal epithelial cell apoptosis | |
| KR20200049647A (ko) | 반려동물에서 종양질병의 보조적 진단을 위한 바이오마커 검사방법 | |
| CA2335773A1 (fr) | Une methode pour evaluer la situation biologique d'une pathologie dans un tissu epithelial | |
| Purcell et al. | Intraductal proliferations of the breast: a review of histologic criteria for atypical intraductal hyperplasia and ductal carcinoma in situ, including apocrine and papillary lesions | |
| US20160033510A1 (en) | Antibodies for the identification of pancreatic disorders | |
| US11448650B2 (en) | Methods for diagnosing high-risk cancer using polysialic acid and one or more tissue-specific biomarkers | |
| US10598664B2 (en) | Epithelial quantitation of histologically normal prostate tissue predicts the presence of cancer in tissue biopsies | |
| CA2176508C (fr) | Examen de depistage pour la detection precoce d'une neoplasie colorectale | |
| Lampertico et al. | Cancer of the Breast: Clinicopathological Correlations in Primary, Recurrent, and Metastatic Tumors with Histochemically Determined Hormone Receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |